OncoMatch/Clinical Trials/NCT07162181
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Is NCT07162181 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pirtobrutinib for lymphoma, non-hodgkin.
Treatment: Pirtobrutinib — The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify